Advertisement Sanford-Burnham, Daiichi Sankyo to develop new therapies for cardiovascular-metabolic diseases - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sanford-Burnham, Daiichi Sankyo to develop new therapies for cardiovascular-metabolic diseases

US-based Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Japanese firm Daiichi Sankyo have entered into a three-year comprehensive alliance for the development of first-in-class therapeutics indicated to treat cardiovascular-metabolic diseases.

The deal, which is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development, is focused on identifying, validating, and screening novel drug targets, and studying new mechanisms of disease.

The team at Sanford-Burnham will identify and validate targets in collaboration with Cardiovascular-Metabolics Research Laboratories at Daiichi Sankyo.

Following the validation of the targets, collaboration teams will carry out drug screening to identify compounds that modulate the targets using facilities at both sites.

Sanford-Burnham professor and director of the Cardiovascular Pathobiology Program Dwight Towler said the partnership will focus on the broad area of cardiovascular-metabolic diseases, which is a primary research area for the company as well as a critical unmet medical need worldwide.

"Strategic partnerships such as this one serve as a key component of our Institute’s 10-year vision to translate basic research discoveries into innovative therapies more quickly," Towler said.

"Today’s announcement represents another milestone for Sanford-Burnham as we connect our expertise in both basic research and drug discovery technology with pharmaceutical partners to implement this patient-oriented initiative."

Daiichi Sankyo corporate officer and global head of Research Masahiko Ohtsuki said, "The cardiovascular-metabolic area is a key priority for Daiichi Sankyo and we have found a strong, strategic partner in Sanford-Burnham."